Bioventus Inc.
BVS
$6.55
$0.121.87%
NASDAQ
| 03/29/2025 | 12/31/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 123.88M | 153.64M | 138.96M | 151.22M | 129.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 123.88M | 153.64M | 138.96M | 151.22M | 129.46M |
| Cost of Revenue | 40.82M | 50.99M | 45.41M | 47.58M | 41.08M |
| Gross Profit | 83.06M | 102.66M | 93.55M | 103.64M | 88.38M |
| SG&A Expenses | 73.48M | 86.53M | 81.04M | 82.28M | 78.78M |
| Depreciation & Amortization | 1.59M | 1.77M | 2.07M | 2.06M | 1.76M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 118.90M | 142.53M | 132.33M | 135.91M | 124.23M |
| Operating Income | 4.97M | 11.11M | 6.64M | 15.30M | 5.22M |
| Income Before Tax | -3.42M | 232.00K | -4.83M | -39.45M | -5.47M |
| Income Tax Expenses | -95.00K | 550.00K | 589.00K | -7.34M | 907.00K |
| Earnings from Continuing Operations | -3.32M | -318.00K | -5.42M | -32.11M | -6.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 685.00K | 162.00K | 597.00K | 8.12M | 1.49M |
| Net Income | -2.64M | -156.00K | -4.82M | -23.99M | -4.89M |
| EBIT | 4.97M | 11.11M | 6.64M | 15.30M | 5.22M |
| EBITDA | 16.84M | 15.90M | 18.91M | 28.39M | 17.01M |
| EPS Basic | -0.04 | 0.00 | -0.07 | -0.37 | -0.08 |
| Normalized Basic EPS | -0.02 | 0.03 | -0.01 | 0.18 | -0.03 |
| EPS Diluted | -0.04 | 0.00 | -0.07 | -0.37 | -0.08 |
| Normalized Diluted EPS | -0.02 | 0.03 | -0.01 | 0.18 | -0.03 |
| Average Basic Shares Outstanding | 66.01M | 65.45M | 65.26M | 64.06M | 63.38M |
| Average Diluted Shares Outstanding | 66.01M | 65.45M | 65.26M | 64.06M | 63.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |